Published in Cancer Weekly, December 7th, 2004
The reason the drug looks promising is that even the one-third of people who didn't lose weight on rimonabant, or Acomplia, still had improvements in cholesterol and other heart-disease risk factors, said Douglas Greene, MD, vice president for corporate and regulatory affairs for Sanofi-Aventis, the French company developing the drug.
He also gave the first details on its safety and side effects, including the one major concern...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.